See more : Gladiator Metals Corp. (GDTRF) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Carlyle Secured Lending, Inc. (CGBD) Income Statement Analysis – Financial Results
- Earthstahl & Alloys Limited (EARTH.BO) Income Statement Analysis – Financial Results
- Farmers Bancorp (Frankfort IN) (FABP) Income Statement Analysis – Financial Results
- Christian Dior SE (CHDRY) Income Statement Analysis – Financial Results
- Cedar Realty Trust, Inc. (CDR) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
| General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
| Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
| Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
| Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
| EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
| Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
| Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
| Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for...
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Additional analysis of week 36 data from the Phase 2b ORIGIN study of atacicept demonstrating resolution of hematuria in the majority of IgAN patients.
Vera Therapeutics Scheduled to Present at November Investor Conferences
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present...
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept's potential as long-term disease-modifying IgAN therapy...
Why Shares of Vera Therapeutics Jumped Tuesday
Vera Therapeutics focuses on autoimmune disorders. The company's lead therapy candidate, atacicept, is in a phase 3 trial.
Vera Therapeutics' Promising Atacicept Drug Targets IgAN
Vera Therapeutics is developing atacicept, a treatment for IgA nephropathy, which showed positive results in Phase 2b trials. The company has strong financials with a cash runway of over two years, but posted an increased net loss in the recent...
What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock
Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports